IP Library Granted Patent US 9,439,911
Granted Patent B2
US 9,439,911 · App. 15/135,298 · Granted Sep 13, 2016

Topical formulations comprising a steroid

Inventors: Udhumansha Ubaidulla (Namakkal, IN); Sateesh Kandavilli (Hyderabad, IN); Ajay Sunil Vairale (Hyderabad, IN); Jeffrey A. Wayne (Markham, CA); Vijendra Nalamothu (Basking Ridge, NJ); Mistry Meghal (Ahmedabad, IN); Refika Isil Pakunlu (Highland Park, NJ)
Assignee: Dr. Reddy's Laboratories Ltd.
A61K31/573A61K9/0014A61K47/26A61K47/36
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,439,911
App. No.
15/135,298
Granted
Sep 13, 2016
Kind
B2
Abstract

The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.

Claims (42)

1. A sprayable topical pharmaceutical composition, comprising:

at least one steroid;

a non-polymeric emulsifying agent comprising sorbitan stearate;

water; and

a water-immiscible substance;

wherein the composition is substantially non-occlusive to the skin.

2. The composition according to claim 1 , wherein the steroid is selected from the group consisting of alclometasone dipropionate, beclomethasone dipropionate, betamethasone dipropionate, betamethasone valerate, fluocinolone acetonide, halobetasol propionate, hydrocortisone aceponate, hydrocortisone acetate, hydrocortisone valerate, hydrocortisone butyrate, mometasone furoate, triamcinolone acetonide, clocortolone pivalate, clobetasol propionate, desoximetasone, and fluticasone propionate.

3. The composition according to claim 1 , and further comprising a polymer.

4. The composition according to claim 3 , wherein the polymer is selected from the group consisting of a cellulose, a gum, an alginate, and a phthalate.

5. The composition according to claim 3 , wherein the polymer is selected from the group consisting of ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, hydroxybutyl methyl cellulose, xanthan gum, tragacanth, guar gum, locust bean gum, acacia, alginate, cellulose acetate phthalate, cellulose acetate butyrate, hydroxypropyl methylcellulose phthalate, and any combination thereof.

6. The composition according to claim 1 , wherein the water-immiscible substance is selected from the group consisting of vegetable oil, saturated paraffin oil, mineral oil, fatty acid, fatty ester of a natural fatty acid, triglyceride of animal or vegetable origin, medium chain triglyceride, mixture of mono-, di- and/or tri-glycerides, wax, hydrogenated vegetable oil, and any combination thereof.

7. The composition according to claim 1 , and further comprising a penetration enhancer.

8. The composition according to claim 7 , wherein the penetration enhancer is in amounts of about 0.001 percent to about 15 percent by weight.

9. The composition according to claim 8 , wherein the penetration enhancer is selected from the group consisting of a polyol and esters, ethers, sulfoxides, fatty acids, fatty acid esters, and any combination thereof.

10. The composition according to claim 3 , wherein

the steroid is selected from the group consisting of betamethasone dipropionate and betamethasone valerate; and

polymer is selected from the group consisting of ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxybutyl methyl cellulose, and any combination thereof.

11. The composition of claim 1 , wherein the composition forms droplets upon application.

12. The composition of claim 1 , wherein the composition is substantially non-foaming.

13. The composition of claim 1 , wherein said composition is substantially free of a propellant.

14. The composition of claim 1 , wherein the composition is substantially free of propylene glycol.

15. A sprayable topical pharmaceutical composition, comprising:

a betamethasone compound;

a non-polymeric emulsifying agent comprising sorbitan stearate;

water; and

a water-immiscible substance;

wherein the topical pharmaceutical composition is is substantially non-occlusive to the skin.

16. The composition according to claim 15 , wherein the betamethasone compound is in amounts equivalent to about 0.025 to about 0.1 percent by weight of betamethasone base.

17. The composition according to claim 15 , wherein the betamethasone compound is betamethasone benzoate, betamethasone dipropionate, betamethasone sodium phosphate, or betamethasone valerate.

18. The composition according to claim 15 , comprising a polymer selected from the group consisting of a cellulose, a gum, an alginate, and a phthalate.

19. The composition according to claim 15 , wherein the polymer is selected from the group consisting of ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, hydroxybutyl methyl cellulose, xanthan gum, tragacanth, guar gum, locust bean gum, acacia, alginate, cellulose acetate phthalate, cellulose acetate butyrate, hydroxypropyl methylcellulose phthalate, and any combination thereof.

20. The composition according to claim 15 , wherein the water-immiscible substance is selected from the group consisting of vegetable oil, saturated paraffin oil, mineral oil, fatty acid, fatty ester of a natural fatty acid, triglyceride of animal or vegetable origin, medium chain triglyceride, mixture of mono-, di- and/or tri-glycerides, wax, hydrogenated vegetable oil, and any combination thereof.

21. The composition according to claim 15 , and further comprising a penetration enhancer.

22. The composition of claim 21 , wherein the penetration enhancer is in amounts of about 0.001 percent to about 15 percent by weight.

23. The composition according to claim 15 , wherein the betamethasone compound is betamethasone dipropionate; and the polymer is selected from the group consisting of ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxybutyl methyl cellulose, and any combination thereof.

24. The composition according to claim 15 , wherein the viscosity of the composition is in the range of about 10 to about 15,000 centipoise.

25. The composition of claim 15 , wherein the composition forms droplets upon application.

26. The composition of claim 15 , wherein the composition is substantially non-foaming.

27. The composition of claim 15 , wherein said composition is substantially free of a propellant.

28. The composition of claim 15 , wherein the composition is substantially free of propylene glycol.

29. A method of treating a skin condition comprising administering pharmaceutically effective amount of the composition according to claim 1 to a subject in need thereof, wherein the condition is selected from one or more of atopic dermatitis, seborrhoeic dermatitis, eczema, plaque psoriasis, erythroderma psoriasis, and psoriasis of the scalp, steroid responsive dermatoses, erythema, or contact sensitivity reactions, and other associated diseases or disorders.

30. A method of treating a skin condition comprising administering pharmaceutically effective amount of the composition according to claim 15 to a subject in need thereof, wherein the condition is selected from one or more of atopic dermatitis, seborrhoeic dermatitis, eczema, plaque psoriasis, erythroderma psoriasis, and psoriasis of the scalp, steroid responsive dermatoses, erythema, or contact sensitivity reactions, and other associated diseases or disorders.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2021
From: ENCORE DERMATOLOGY, INC.
To: PRIMUS PHARMACEUTICALS, INC.
Reel/Frame 055576/0523 →
SECURITY INTEREST Recorded Nov 11, 2020
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: PENNRX VENTURES, LLC
Reel/Frame 054337/0330 →
SECURITY INTEREST Recorded Apr 22, 2019
From: ENCORE DERMATOLOGY, INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 048958/0284 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2019
From: PROMIUS PHARMA, LLC
To: ENCORE DERMATOLOGY, INC.
Reel/Frame 048941/0640 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2017
From: DR. REDDY'S LABORATORIES LTD.
To: PROMIUS PHARMA LLC
Reel/Frame 042704/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2017
From: UBAIDULLA, UDHUMANSHA; KANDAVILLI, SATEESH; WAYNE, JEFFREY A.; PAKUNLU, REFIKA ISIL; NALAMOTHU, VIJENDRA; MEGHAL, MISTRY; VAIRALE, AJAY SUNIL
To: DR. REDDY'S LABORATORIES LTD
Reel/Frame 041311/0565 →
Priority Claims (1)
IN 2111/CHE/2009 · Aug 31, 2009 · national
Continuity (3)
Continuation 13391972
Provisional Application 61256554 · Oct 30, 2009
Related Publication 20160235768A1 · Aug 18, 2016